Ticker: ABEO

Abeona Therapeutics Inc. (NASDAQ: ABEO) - What's happening inside the company Abeona received FDA approval for ZEVASKYN™ on April 28, 2025, sold the associated Priority Review Voucher (PRV) for gross proceeds of $155.0 million (closed June 27, 2025), has established cGMP commercial manufacturing ...

Abeona Therapeutics Inc. (NASDAQ: ABEO) has reported its financial results for the quarter ended March 31, 2025, with significant developments impacting its financial health and operational outlook. Key Highlights: FDA Approval: The company received FDA approval for ZEVASKYN™, the first autologo...